Products
Solutions
Resources
Pricing
Security
Products
IP
Patent Search & Analysis
Novelty Search
FTO Search
Design FTO Search
Patent Drafting & OAR
SEP Assessment
Engineering
Tech Research & Engineering Solutions
Find Solutions with TRIZ
Life Sciences
Drug Discovery & Research
SAR Data Extraction
Lead Compound
Materials R&D
Materials Research & Development
MCP Servers
REST APIs
Skill Hub
UI Widgets
Desktop
Beta
Solutions
Featured Use Cases
Competitor Tech Research
Design Risk Screening
Cosmetic Formulation
Telecom SEP Claim Chart
Resources
Featured Guides
Patentability Search vs. FTO
Find Prior Art
Review FTO Evidence
Discover
Free AI Tools
Benchmark Reports
Blog & Insights
Support
Help Center
Community & Socials
LinkedIn
X
YouTube
Substack
Pricing
Security
Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.
1
results about "Dexrazoxane" patented technology
Filter
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Dexrazoxane is used to reduce the risk and severity of heart damage caused by doxorubicin treatment and similar cancer chemotherapy medications.
Application of MSR1 inhibitor in preparation of anti-tumor immunopotentiator
Pending
CN122075696A
Organic active ingredients
Antibody ingredients
Cytokine
Tumor Subtype
The invention discloses an application of an MSR1 inhibitor in preparation of an anti-tumor
immunopotentiator
. The MSR1 inhibitor is composed of doxylamine, trafenotide,
dexrazoxane
and
clavulanic acid
. The invention discloses application of an MSR1 inhibitor combined with an
immune checkpoint
inhibitor in preparation of a
medicine
for treating
solid
tumors. The MSR1 inhibitor disclosed by the invention is used as an anti-tumor
immunopotentiator
and is combined with an
immune checkpoint
inhibitor to treat
solid
tumors, so that the
curative effect
of tumor
immunotherapy
can be improved. The MSR1 inhibitor can induce tumor-related macrophages to be differentiated into anti-tumor subtypes, anti-
tumor immunity
is driven through
phagocytosis
and generation of
cell
factors, and a new method is provided for improving the
curative effect
of tumor
immunotherapy
.
View all
Owner:
JIANGSU PROVINCE HOSPITAL (THE FIRST AFFILIATED HOSPITAL OF NANJING MEDICAL UNIVERSITY)
Login to View More